2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1110

Expanding Access to Research Using Tele-Health: Lupus and Informatics Feasibility Study
Abstract Number: 2156

Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome
Abstract Number: 607

Expansion of Peripheral Cytotoxic T Cells in Co-morbid Inflammatory Bowel Disease and Spondyloarthritis
Abstract Number: 375

Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center
Abstract Number: 1770

Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Abstract Number: 535

Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA
Abstract Number: 2850

Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
Abstract Number: 183

Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
Abstract Number: 2797

Exploring Possible Predictors of Physical Activity in Knee Replacement Patients
Abstract Number: 2339

Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Abstract Number: 1492

Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
Abstract Number: 1556

Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
Abstract Number: 2016

Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis
Abstract Number: 2044

Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice
Abstract Number: 1405

Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].